PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31572383-13 2019 Dexamethasone and budesonide induced sftpd transcription and translation in human type II alveolar epithelial cells in a glucocorticoid receptor and STAT3 (an IL-6 responsive transcription factor) dependent manner. Budesonide 18-28 nuclear receptor subfamily 3 group C member 1 Homo sapiens 121-144 23625588-3 2014 In the present study, we investigated the potential additive or synergistic inhibitory effects on cancer cell proliferation by simultaneous application of fenofibrate and budesonide, agonists for PPARalpha and glucocorticoid receptor, respectively. Budesonide 171-181 nuclear receptor subfamily 3 group C member 1 Homo sapiens 210-233 23562201-0 2013 Effects of budesonide on the expression of the glucocorticoid receptor-alpha in nasal polyp epithelial cells. Budesonide 11-21 nuclear receptor subfamily 3 group C member 1 Homo sapiens 47-70 24880571-6 2014 RESULTS: Most of the compounds (hydrocortisone, betamethasone, flumethasone, triamcinolone, budesonide, fluticasone propionate, and fludrocortisone acetate) increased GR-positive cell growth, which was similar to or even stronger than the effect of dexamethasone. Budesonide 92-102 nuclear receptor subfamily 3 group C member 1 Homo sapiens 167-169 24627531-4 2014 The mechanism behind the effect of budesonide-induced CCL20 production was studied in 16HBE14o- cells using inhibitors for the glucocorticoid receptor, intracellular pathways and metalloproteases. Budesonide 35-45 nuclear receptor subfamily 3 group C member 1 Homo sapiens 127-150 24627531-10 2014 Inhibition of glucocorticoid receptor or ADAM17 abrogated the budesonide-induced increase in CCL20 levels. Budesonide 62-72 nuclear receptor subfamily 3 group C member 1 Homo sapiens 14-37 23562201-1 2013 BACKGROUND: This study explores effects of budesonide on the proliferation of nasal polyp epithelial cells and expression of the glucocorticoid receptor (GR) alpha in nasal polyp epithelial cells. Budesonide 43-53 nuclear receptor subfamily 3 group C member 1 Homo sapiens 4-6 21434575-1 2011 Budesonide is a potent glucocorticoid with high affinity for the glucocorticoid receptor, which is used for the treatment of inflammatory bowel diseases. Budesonide 0-10 nuclear receptor subfamily 3 group C member 1 Homo sapiens 65-88 21875545-7 2011 RESULTS: Budesonide enhanced IgE synthesis to higher extent in healthy donors than in allergic patients (mean increase of 16.5 vs 6.3 kU/L, P< .05 respectively) acting through glucocorticoid receptor. Budesonide 9-19 nuclear receptor subfamily 3 group C member 1 Homo sapiens 179-202 21878659-8 2011 Budesonide is an orally administered synthetic corticosteroid with high affinity for the glucocorticoid receptor that undergoes extensive first-pass metabolism. Budesonide 0-10 nuclear receptor subfamily 3 group C member 1 Homo sapiens 89-112 17596271-3 2007 The present study investigates the effects of formoterol (FORM), salmeterol (SALM) and budesonide (BUD) on GR activation in bronchial epithelial cells via tumour necrosis factor-alpha-stimulated granulocyte-macrophage colony-stimulating factor (GM-CSF) release, GR nuclear translocation and GR-regulated reporter gene activity. Budesonide 87-97 nuclear receptor subfamily 3 group C member 1 Homo sapiens 107-109 18414714-3 2008 Budesonide, a synthetic glucocorticoid, undergoes a high degree of first-pass metabolism, reducing its systemic bioavailability, and has a 15-fold greater affinity for the glucocorticoid receptor than prednisolone. Budesonide 0-10 nuclear receptor subfamily 3 group C member 1 Homo sapiens 172-195 17596271-3 2007 The present study investigates the effects of formoterol (FORM), salmeterol (SALM) and budesonide (BUD) on GR activation in bronchial epithelial cells via tumour necrosis factor-alpha-stimulated granulocyte-macrophage colony-stimulating factor (GM-CSF) release, GR nuclear translocation and GR-regulated reporter gene activity. Budesonide 99-102 nuclear receptor subfamily 3 group C member 1 Homo sapiens 107-109 14684580-9 2004 Reporter constructs of the human ASBT promoter were activated 15-20-fold by coexpression of the glucocorticoid receptor (GR) and exposure to the GR ligands dexamethasone or budesonide. Budesonide 173-183 nuclear receptor subfamily 3 group C member 1 Homo sapiens 145-147 8977508-4 1996 Peripheral blood mononuclear cell GCR binding affinities for dexamethasone and budesonide were also determined for both patient groups by using a radioligand binding assay and Scatchard analysis. Budesonide 79-89 nuclear receptor subfamily 3 group C member 1 Homo sapiens 34-37 14519035-5 2003 DATA SYNTHESIS: Budesonide"s high potency at the glucocorticoid receptor and extensive first-pass hepatic metabolism result in a topical antiinflammatory effect on intestinal tissue, with minimal systemic glucocorticoid adverse effects. Budesonide 16-26 nuclear receptor subfamily 3 group C member 1 Homo sapiens 49-72 12601049-10 2003 CONCLUSIONS: Budesonide is capable of inhibiting VEGF expression through glucocorticoid receptor activity. Budesonide 13-23 nuclear receptor subfamily 3 group C member 1 Homo sapiens 73-96 11730731-8 2001 The present data suggests that budesonide and fluticasone propionate prolong human neutrophil survival by inhibiting apoptosis at clinically relevant drug concentrations via an effect on glucocorticoid receptor. Budesonide 31-41 nuclear receptor subfamily 3 group C member 1 Homo sapiens 187-210 11502275-5 2001 At concentrations devoid of cytotoxicity, budesonide reduced VEGF secretion and VEGF mRNA expression in both cell types and these effects were inhibited by mifepristone (RU 486), a glucocorticoid receptor antagonist, suggesting that budesonide reduces VEGF secretion and expression through its glucocorticoid receptor-mediated action. Budesonide 42-52 nuclear receptor subfamily 3 group C member 1 Homo sapiens 181-204 11502275-5 2001 At concentrations devoid of cytotoxicity, budesonide reduced VEGF secretion and VEGF mRNA expression in both cell types and these effects were inhibited by mifepristone (RU 486), a glucocorticoid receptor antagonist, suggesting that budesonide reduces VEGF secretion and expression through its glucocorticoid receptor-mediated action. Budesonide 42-52 nuclear receptor subfamily 3 group C member 1 Homo sapiens 294-317 11258648-0 2001 Effects of topical budesonide treatment on glucocorticoid receptor mRNA down-regulation and cytokine patterns in nasal polyps. Budesonide 19-29 nuclear receptor subfamily 3 group C member 1 Homo sapiens 43-66 11258648-1 2001 UNLABELLED: The effects of a topically applied corticosteroid, budesonide, on the expression of glucocorticoid receptor (GR) mRNA and regulation of pro-inflammatory cytokine patterns in patients with nasal polyps were evaluated. Budesonide 63-73 nuclear receptor subfamily 3 group C member 1 Homo sapiens 96-119 11258648-1 2001 UNLABELLED: The effects of a topically applied corticosteroid, budesonide, on the expression of glucocorticoid receptor (GR) mRNA and regulation of pro-inflammatory cytokine patterns in patients with nasal polyps were evaluated. Budesonide 63-73 nuclear receptor subfamily 3 group C member 1 Homo sapiens 121-123 11040338-7 2000 The results suggest that fluticasone and budesonide induce eosinophil apoptosis at clinically achievable drug concentrations via an effect on glucocorticoid receptor. Budesonide 41-51 nuclear receptor subfamily 3 group C member 1 Homo sapiens 142-165 9795066-0 1998 Binding kinetics of budesonide to the human glucocorticoid receptor. Budesonide 20-30 nuclear receptor subfamily 3 group C member 1 Homo sapiens 44-67 12920235-0 2003 Identification of a novel glucocorticoid receptor mutation in budesonide-resistant human bronchial epithelial cells. Budesonide 62-72 nuclear receptor subfamily 3 group C member 1 Homo sapiens 26-49 12920235-1 2003 We developed a molecular genetic model to investigate glucocorticoid receptor (GR) signaling in human bronchial epithelial cells in response to the therapeutic steroid budesonide. Budesonide 168-178 nuclear receptor subfamily 3 group C member 1 Homo sapiens 54-77 12920235-1 2003 We developed a molecular genetic model to investigate glucocorticoid receptor (GR) signaling in human bronchial epithelial cells in response to the therapeutic steroid budesonide. Budesonide 168-178 nuclear receptor subfamily 3 group C member 1 Homo sapiens 79-81 12920235-3 2003 Three spontaneous budesonide-resistant subclones were found to express low levels of GR, whereas two mutants isolated from ethylmethane sulfonate-treated cultures contained normal levels of GR protein. Budesonide 18-28 nuclear receptor subfamily 3 group C member 1 Homo sapiens 85-87 12920235-4 2003 Analysis of the GR coding sequence in the budesonide-resistant subclone Ch-BdE5 identified a novel Val to Met mutation at amino acid position 575 (GRV575M) which caused an 80% decrease in transcriptional regulatory functions with only a minimal effect on ligand binding activity. Budesonide 42-52 nuclear receptor subfamily 3 group C member 1 Homo sapiens 16-18 9795066-1 1998 Glucocorticoid receptor-ligand binding kinetics of budesonide, a glucocorticoid used for inhalation therapy, were determined and compared with dexamethasone and fluticasone propionate using glucocorticoid receptors from human lung tissue. Budesonide 51-61 nuclear receptor subfamily 3 group C member 1 Homo sapiens 0-23 8977508-9 1996 The GCR binding affinity for budesonide was significantly higher in both groups (i.e., lower dissociation constant) than that obtained for dexamethasone. Budesonide 29-39 nuclear receptor subfamily 3 group C member 1 Homo sapiens 4-7 8977508-10 1996 CONCLUSION: These data suggest that glucocorticoids such as budesonide, by virtue of their high GCR binding affinities and greater ability to suppress lymphocyte proliferation, may therefore be beneficial in the management of difficult-to-control asthma. Budesonide 60-70 nuclear receptor subfamily 3 group C member 1 Homo sapiens 96-99 7604948-3 1995 It has an absolute affinity (KD) of 0.5 nM for the glucocorticoid receptor and a relative receptor affinity 1.5- and 3.0-times greater than that of beclomethasone-17-monopropionate (17-BMP) and budesonide, respectively. Budesonide 194-204 nuclear receptor subfamily 3 group C member 1 Homo sapiens 51-74 8713673-4 1996 Variation at the glucocorticoid receptor locus can be identified as a biallelic restriction fragment length polymorphism (Bcl1); subjects with contrasting genotypes show altered skin vasoconstrictor responses to topically applied budesonide without any significant change in leucocyte receptor binding characteristics. Budesonide 230-240 nuclear receptor subfamily 3 group C member 1 Homo sapiens 17-40 8621851-0 1996 Regulation of glucocorticoid receptor mRNA in nasal mucosa by local administration of fluticasone and budesonide. Budesonide 102-112 nuclear receptor subfamily 3 group C member 1 Homo sapiens 14-37